Volunteer Today for Type 1 Diabetes Studies

NIAID is committed to advancing the understanding of autoimmune diseases such as type 1 diabetes and to conducting clinical studies to develop effective prevention and treatment strategies.

A Research Trial of Aralast in New Onset Diabetes

This is a two-part study to investigate the effect of intravenous Alpha-1 Antitrypsin (AAT) on preserving insulin-producing beta cell function and to determine if AAT will help slow the progression of type 1 diabetes.

• Part I (NCT01183468) is an open-label, safety and dose level study consisting of two groups - Part Ib of this study is expected to start enrolling volunteers in March 2013.
• Part II (NCT01183455) is a two-arm, double-blind, placebo-controlled study where volunteers will be randomly assigned to either a treatment and placebo group. Recruitment for this part of the study will begin after Part I is completed.

Read more about this study and find site locations at the study website.

Inducing Remission in Type 1 Diabetes With Alefacept (NCT00965458)

This study evaluates whether the drug alefacept will halt or slow the destruction of insulin-producing beta cells in the pancreas. This study is on-going but not recruiting volunteers.

Read more about this study and find site locations on ClinicalTrials.gov and at the study website.

See more NIAID-supported diabetes studies that are seeking volunteers on ClinicalTrials.gov.

The National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) also sponsors research related to type 1 diabetes. Find out more about NIDDK-supported Type 1 diabetes research, including studies currently recruiting participants.